{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:39:52Z","timestamp":1761964792826},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.beha.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T12:31:57Z","timestamp":1476966717000},"page":"345-350","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Should anyone with Philadelphia chromosome-positive ALL who is negative for\u00a0minimal residual disease receive a hematopoietic stem cell transplant in first remission?"],"prefix":"10.1016","volume":"29","author":[{"given":"Mark R.","family":"Litzow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.10.009_bib1","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib3","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.3747\/co.21.1834","article-title":"Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus","volume":"21","author":"Couban","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.beha.2016.10.009_bib4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.009_bib5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V126.23.796.796","article-title":"Multi-center US Intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60","volume":"126","author":"Ravandi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib8","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.009_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T20:29:10Z","timestamp":1601152150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1521692616300627"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.009","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should anyone with Philadelphia chromosome-positive ALL who is negative for\u00a0minimal residual disease receive a hematopoietic stem cell transplant in first remission?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}